Back to discover
Disease

insulin-resistance syndrome type A

Late-stage therapeutic development
Also known as insulin resistant diabetes mellitus with acanthosis nigricans and hyperandrogenism, type A insulin resistance syndrome, Iran, type a, diabetes mellitus, insulin-resistant, with acanthosis nigricans+3 more

insulin resistant diabetes mellitus with acanthosis nigricans and hyperandrogenism, type A insulin resistance syndrome, Iran, type a, diabetes mellitus, insulin-resistant, with acanthosis nigricans, diabetes mellitus, insulin-resistant, with acanthosis nigricans, type a, insulin receptor, defect in, with insulin-resistant diabetes mellitus and acanthosis nigricans, insulin-resistant acanthosis nigricans, type A.

24
Clinical trials
2
Associated genes
1
Related proteins
Current focus
Insulin biologyTherapeutic developmentMetabolic & lifestyle factors

What's happening now

An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.

Executive briefingUpdating summary…Momentum: Moderate
Key developments
  • 5 clinical trials expected to report results, the earliest in Q2 2027.
Upcoming Milestones
Clinical Milestones9View all 9
Results posted 2
Results expected 5
Recently completed 2
+1 more in the activity timeline below
Activity timeline9

Clinical trials

17 sponsors · 4 new · 2 completed in the last 12 months (net +4)

The current development programme across all trial phases.

Clinical programme
24
All trials
6
Active
18
Late-stage
6
Completed
Late-stage studies

Multifactorial Intervention to Reduce Cardiovascular Disease in Type 1 Diabetes

Phase 3 · Recruiting · Steno Diabetes Center Copenhagen

Effectiveness and Safety of Sotagliflozin in Slowing Kidney Function Decline in Persons With Type 1 Diabetes and Moderate to Severe Diabetic Kidney Disease

Phase 3 · Recruiting · Alessandro Doria

Fully Closed-Loop Glucose Control in Adults With Type 1 Diabetes Using Tirzepatide: a Randomized, Multi-center, Open-label, Non-inferiority, Parallel Trial

Phase 2/3 · Recruiting · McGill University Health Centre/Research Institute of the McGill University Health Centre

A Single-Center, Randomized, Double-Blind, Placebo-Controlled Clinical Trial Evaluating the Efficacy and Safety of Dimethyl Fumarate in Preserving Islet β-Cell Function in Patients With Type 1 Diabetes Mellitus

Phase 3 · Recruiting · Nanjing Medical University

Non-Randomized, Parallel-Controlled, Single-Center, Open-Label Clinical Trial Evaluating the Efficacy and Safety of Dimethyl Fumarate in Preserving Pancreatic β-Cell Function in Adults With Type 1 Diabetes

Phase 2/3 · Recruiting · Nanjing Medical University

Permissive Versus Strict Intrapartum Glucose Management in Type 1 Diabetes (PRISM-T1D)

Phase 4 · Recruiting · Ohio State University
Recruiting

Multifactorial Intervention to Reduce Cardiovascular Disease in Type 1 Diabetes

Phase 3 · Recruiting · Steno Diabetes Center Copenhagen

Effectiveness and Safety of Sotagliflozin in Slowing Kidney Function Decline in Persons With Type 1 Diabetes and Moderate to Severe Diabetic Kidney Disease

Phase 3 · Recruiting · Alessandro Doria

Fully Closed-Loop Glucose Control in Adults With Type 1 Diabetes Using Tirzepatide: a Randomized, Multi-center, Open-label, Non-inferiority, Parallel Trial

Phase 2/3 · Recruiting · McGill University Health Centre/Research Institute of the McGill University Health Centre

A Single-Center, Randomized, Double-Blind, Placebo-Controlled Clinical Trial Evaluating the Efficacy and Safety of Dimethyl Fumarate in Preserving Islet β-Cell Function in Patients With Type 1 Diabetes Mellitus

Phase 3 · Recruiting · Nanjing Medical University

Non-Randomized, Parallel-Controlled, Single-Center, Open-Label Clinical Trial Evaluating the Efficacy and Safety of Dimethyl Fumarate in Preserving Pancreatic β-Cell Function in Adults With Type 1 Diabetes

Phase 2/3 · Recruiting · Nanjing Medical University

Permissive Versus Strict Intrapartum Glucose Management in Type 1 Diabetes (PRISM-T1D)

Phase 4 · Recruiting · Ohio State University
Recently completed

Effect of Sodium-Glucose Cotransporter (SGLT) 2 Inhibitors on Diabetic Nephropathy Progression in Adolescents With Type 1 Diabetes Mellitus

Phase 2/3 · Completed · Ain Shams University

A Parallel-group, Randomized, Prospective, Interventional, Double-blind, Multicenter Global Phase 3 Study to Investigate the Efficacy and Safety of Finerenone Versus Placebo, in Addition to Standard of Care, in Participants With Chronic Kidney Disease and Type 1 Diabetes

Phase 3 · Completed · Bayer

A Phase 3, Randomized, Open-Label, Multicenter, Active-controlled Trial Comparing Efficacy and Safety of THDB0206 Injection With Insulin Lispro Injection Combined With Insulin Glargine Injection U-100 in Chinese Participants With Type 1 Diabetes

Phase 3 · Completed · Tonghua Dongbao Pharmaceutical Co.,Ltd

Phase 3, Single-administration, Open-label Trial to Assess the Efficacy, Safety, PK, and PD of Dasiglucagon When Administered as a Rescue Therapy for Severe Hypoglycemia in Pediatric Patients Below 6 Years of Age With Type 1 Diabetes (T1D)

Phase 3 · Completed · Zealand Pharma

Human Versus Analogue Insulin for Youth With Type 1 Diabetes in Low-Resource Settings: A Randomized Controlled Trial

Phase 4 · Completed · Jing Luo

A Phase 3 Single Center Study of Islet Transplantation in Non-uremic Diabetic Patients

Phase 3 · Completed · Northwestern University

Associated genes

2 matches

Genes associated with this disease in the canonical knowledge graph (Open Targets evidence). Number shows the association score.

INSR0.84INSM20.04

Disease biology

1 match

Proteins whose encoding gene is associated with this disease, reached through the canonical gene→disease graph. Number shows the gene's association score.

Insulin receptorvia INSR0.84

Reference

Authoritative identity, definition & identifiers.

Synonyms

insulin resistant diabetes mellitus with acanthosis nigricans and hyperandrogenism, type A insulin resistance syndrome, Iran, type a, diabetes mellitus, insulin-resistant, with acanthosis nigricans, diabetes mellitus, insulin-resistant, with acanthosis nigricans, type a, insulin receptor, defect in, with insulin-resistant diabetes mellitus and acanthosis nigricans, insulin-resistant acanthosis nigricans, type A

References & data sources
  • Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
  • Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
  • Related entities are derived from literature co-mention (studied together) — associative, not causal.